{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T15:25:18Z","timestamp":1787325918372,"version":"build-2736575974"},"reference-count":15,"publisher":"Centre for Evaluation in Education and Science (CEON\/CEES)","issue":"6","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/BY\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Biochemistry"],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:p>Background: Mycoplasma pneumoniae pneumonia (MPP) is a common cause of community-acquired pneumonia in children, with pleural effusion (PE) as a recognised but challenging complication. Identifying reliable biomarkers to predict PE in MPP is crucial for timely intervention. This study aims to evaluate the prognostic value of serum C-reactive protein (CRP), Immunoglobulin M (IgM), and Immunoglobulin A (IgA) levels in children with MPP and PE. Methods: A retrospective study was conducted on 200 pediatric patients diagnosed with MPP between January 2021 and December 2023. Patients were divided into two groups: MPP with PE (n=100) and MPP without PE (n=100). Serum CRP , IgM, and IgA levels were measured, and their associations with PE were analysed using logistic regression models. Results: The MPP with PE group had significantly higher CRP (30.22\u00b124.01 mg\/L vs 9.90\u00b17.01 mg\/L, P&lt;0.001) and IgM (167.39\u00b185.68 mg\/dL vs 130.48\u00b177.65 mg\/dL, P=0.002) levels compared to the MPP without PE group. In contrast, IgA levels were significantly lower in the PE group (164.50\u00b187.22 mg\/dL vs. 195.51\u00b179.93 mg\/dL, P=0.009). Multivariate logistic regression analysis revealed that elevated CRP (OR=1.255, 95% CI: 1.132-1.391, P&lt;0.001) and IgM (OR=1.795, 95% CI: 1.777-4.867, P=0.001) were independent risk factors for PE, while higher IgA levels were protective (OR=0.281, 95% CI: 0.131-0.602, P=0.001). Conclusions: Serum CRP and IgM levels are potential predictors of pleural effusion in children with MPP , while elevated IgA levels may indicate a lower risk. These biomarkers could aid in early risk stratification and guide clinical management to improve outcomes.<\/jats:p>","DOI":"10.5937\/jomb0-54947","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T03:03:10Z","timestamp":1744167790000},"page":"1279-1287","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic value of serum CRP, IgM and IgA levels in children with Mycoplasma pneumoniae and pleural effusion"],"prefix":"10.5937","volume":"44","author":[{"given":"Huiqing","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3964","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Kumar S. Mycoplasma pneumoniae: A significant but underrated pathogen in paediatric community-acquired lower respiratory tract infections. Indian J Med Res. 2018; 147(1): 23-31. doi:10.4103\/ijmr.IJMR_1582_16;","DOI":"10.4103\/ijmr.IJMR_1582_16"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Kim CH, Lee J. Mycoplasma pneumoniae Pleural Effusion in Adults. J Clin Med 2022; 11(5): 1281. Published 2022 Feb 26. doi:10.3390\/jcm11051281;","DOI":"10.3390\/jcm11051281"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Karkhanis VS, Joshi JM. Pleural effusion: diagnosis, treatment, and management. Open Access Emerg Med 2012; 4: 31-52. Published 2012 Jun 22. doi:10.2147\/OAEM.S29942;","DOI":"10.2147\/OAEM.S29942"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Li S, Zhou J, He J, et al. Clinical profiles of Mycoplasma pneumoniae pneumonia in children with different pleural effusion patterns: a retrospective study. BMC Infect Dis 2024; 24(1): 919. Published 2024 Sep 4. doi:10.1186\/s12879-024-09829-5;","DOI":"10.1186\/s12879-024-09829-5"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Ross Y, Ballou S. Reliability of C-reactive protein as an inflammatory marker in patients with immune-mediated inflammatory diseases and liver dysfunction. Rheumatol Adv Pract 2023; 7(2): rkad045. Published 2023 May 2. doi:10.1093\/rap\/rkad045;","DOI":"10.1093\/rap\/rkad045"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Fan F, Lv J, Yang Q, Jiang F. Clinical characteristics and serum inflammatory markers of community-acquired mycoplasma pneumonia in children. Clin Respir J 2023; 17(7): 607-17. doi:10.1111\/crj.13620;","DOI":"10.1111\/crj.13620"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Jing P, Wu C, Du C, Zhou L, Gu L. Predictive value of plasma sICAM-1 and sP-Selectins in the risk of death in patients with acute respiratory distress syndrome. J Med Biochem 2024; 43 (1): 209-18.;","DOI":"10.5937\/jomb0-45340"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Lee WJ, Huang EY, Tsai CM, et al. Role of Serum Mycoplasma pneumoniae IgA, IgM, and IgG in the Diagnosis of Mycoplasma pneumoniae-Related Pneumonia in School-Age Children and Adolescents. Clin Vaccine Immunol 2017; 24(1): e00471-16. Published 2017 Jan 5. doi:10.1128\/CVI.00471-16;","DOI":"10.1128\/CVI.00471-16"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"de Sousa-Pereira P, Woof JM. IgA: Structure, Function, and Developability. Antibodies (Basel) 2019; 8(4): 57. Published 2019 Dec 5. doi:10.3390\/antib8040057;","DOI":"10.3390\/antib8040057"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Kostinov, M., Svitich, O., Chuchalin, A. et al. Secretory IgA and course of COVID-19 in patients receiving a bacteria-based immunostimulant agent in addition to background therapy. Sci Rep 14, 11101 (2024). https:\/\/doi.org\/10.1038\/s41598-024-61341-7;","DOI":"10.1038\/s41598-024-61341-7"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Xu X, Sheng Y, Yang L, Zhou H, Tang L, Du L. Immunological Features of Pediatric Interstitial Pneumonia Due to Mycoplasma pneumoniae. Front Pediatr 2021; 9: 651487. Published 2021 Apr 20. doi:10.3389\/fped.2021.651487;","DOI":"10.3389\/fped.2021.651487"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Han Q, Jiang T, Wang T, et al. Clinical value of monitoring cytokine levels for assessing the severity of mycoplasma pneumoniae pneumonia in children. Am J Transl Res 2024; 16(8): 3964-77. Published 2024 Aug 15. doi:10.62347\/OUPW3987;","DOI":"10.62347\/OUPW3987"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Wang YS, Zhou YL, Bai GN, et al. Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. World J Pediatr 2024; 20(9): 901-14. doi:10.1007\/s12519-024-00831-0;","DOI":"10.1007\/s12519-024-00845-8"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Mouliou DS. C-Reactive Protein: Pathophysiology, Diagnosis, False Test Results and a Novel Diagnostic Algorithm for Clinicians. Diseases 2023; 11(4): 132. Published 2023 Sep 28. doi:10.3390\/diseases11040132;","DOI":"10.3390\/diseases11040132"},{"key":"ref15","unstructured":"Cao X. Monitoring Mycoplasma pneumoniae-Specific Antibody, C-Reactive Protein, and Procalcitonin Levels in Children with Mycoplasma Pneumonia Is Important retracted in: Comput Math Methods Med 2023 Jul 26; 2023: 9781949. doi: 10.1155\/2023\/9781949. Comput Math Methods Med. 2022; 2022: 7976858. Published 2022 Jun 28. doi:10.1155\/2022\/7976858;"}],"container-title":["Journal of Medical Biochemistry"],"original-title":["Prognosti\u010dka vrednost nivoa serumskog CRP-a, IgM-a i IgA kod dece sa mycoplasma pneumoniae i pleuralnim izlivom"],"language":"en","link":[{"URL":"https:\/\/scindeks-clanci.ceon.rs\/data\/pdf\/1452-8258\/2025\/1452-82582506279G.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T11:15:47Z","timestamp":1757070947000},"score":1,"resource":{"primary":{"URL":"https:\/\/scindeks.ceon.rs\/Article.aspx?artid=1452-82582506279G"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5937\/jomb0-54947","relation":{},"ISSN":["1452-8258","1452-8266"],"issn-type":[{"value":"1452-8258","type":"print"},{"value":"1452-8266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}